Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

Abstract Background Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high‐dose interferon (HDI) in patients with resected, high‐risk melanoma. However, the cost of ipilimumab is substantially higher than HDI. This study evaluates the cost‐effectiveness of...

Full description

Bibliographic Details
Main Authors: Mia Salans, Patrick Travis Courtney, Anthony Yip, James D. Murphy
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
cost‐effectiveness
high‐dose interferon
immunotherapy
ipilimumab
melanoma
Online Access:https://doi.org/10.1002/cam4.4194

Internet

https://doi.org/10.1002/cam4.4194

Similar Items